btt-1023
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00851240)
Timeline
Indications
Mechanism of action
- Amine oxidase, copper containingINHIBITOR
AOC3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- btt-1023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02239211 | Phase 2 | Sep 8, 2015 | Biotie Therapies, National Institute for Health Research, United Kingdom, University of Birmingham |
| NCT00871598 | Phase 1 | Mar 1, 2009 | Biotie Therapies |
| NCT00851240 | Phase 1 | Feb 1, 2009 | Biotie Therapies |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotie Therapies | For profit | 3 | 2 | 2 | 2009 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2015 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1